Posted by Michael Wonder on 20 Jan 2016

Speeding up access to new drugs threatens evidence based medicine, says health economist

BMJ

15 January 2016 - Accelerating access to new drugs in the NHS will do more harm than good, asserts Karl Claxton, a health economist at the University of York.

For more details, go to: http://www.bmj.com/content/352/bmj.i263?etoc=

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Health technology assessment , Timelines , Market access , Accelerated approval